Clinical evaluation of serum prostate-specific antigen-apha1-antichymotrypsin complex values in diagnosis of prostate cancer: A cooperative study

Manabu Kuriyama, Kazuya Ueno, Hiromi Uno, Yukimichi Kawada, Susumu Akimoto, Masatoshi Noda, Yasutomo Nasu, Tomoyasu Tsushima, Hiroyuki Ohmori, Hideki Sakai, Yasushi Saito, Norio Meguro, Michiyuki Usami, Toshihiko Kotake, Yuji Suzuki, Yoichi Arai, Jun Shimazaki

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: We studied the clinical significance of serum prostate-specific antigen bound to α1-antichymotrypsin (PSA-ACT) values determined with a newly developed enzyme immunoassay. Methods: Serum PSA-ACT values were determined in a total of 652 sera. Clinical utility for the diagnosis of prostate cancer was compared to that of Tandem-RPSA and γ-seminoprotein (γ-Sm). The new enzyme immunoassay is based on the use of the Stanford reference as an international standard for PSA assays. Results: Serum PSA-ACT values ranged from less than 0.10 to 1.4 ng/mL in healthy males (n = 100) while values in patients with benign prostatic hyperplasia (n = 155) averaged 3.4 ± 3.8 ng/mL (mean ± SD). In patients with prostate cancer, serum PSA-ACT values increased significantly with progression of the clinical stage and there were statistically significant differences between benign prostatic hyperplasia and each stage of prostate cancer except for stage A. Using BPH levels as controls (4.8 ng/mL for PSA-ACT, 7.2 ng/mL for PSA, 3.8 ng/mL for γ-Sm, and 2.4 ng/mL for the complexed/free PSA ratio of PSA-ACT/γ-Sm), specificity was 80%. The sensitivity of prostate cancer detection was 79% for PSA-ACT, 77% for PSA, 57% for γ-Sm, and 46% for the ratio between PSA-ACT/γ-Sm. Conclusion: Although the determination of serum PSA-ACT showed essentially the same utility as that of PSA for the diagnosis of prostate cancer, PSA-ACT may allow prediction of the clinical stage. The PSA-ACT assay may therefore replace PSA in the detection of prostate cancer.

Original languageEnglish
Pages (from-to)48-54
Number of pages7
JournalInternational Journal of Urology
Volume5
Issue number1
Publication statusPublished - 1998

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Serum
Prostatic Hyperplasia
Immunoenzyme Techniques

Keywords

  • Diagnosis
  • Prostate cancer
  • PSA
  • PSA-ACT
  • Screening

ASJC Scopus subject areas

  • Urology

Cite this

Clinical evaluation of serum prostate-specific antigen-apha1-antichymotrypsin complex values in diagnosis of prostate cancer : A cooperative study. / Kuriyama, Manabu; Ueno, Kazuya; Uno, Hiromi; Kawada, Yukimichi; Akimoto, Susumu; Noda, Masatoshi; Nasu, Yasutomo; Tsushima, Tomoyasu; Ohmori, Hiroyuki; Sakai, Hideki; Saito, Yasushi; Meguro, Norio; Usami, Michiyuki; Kotake, Toshihiko; Suzuki, Yuji; Arai, Yoichi; Shimazaki, Jun.

In: International Journal of Urology, Vol. 5, No. 1, 1998, p. 48-54.

Research output: Contribution to journalArticle

Kuriyama, M, Ueno, K, Uno, H, Kawada, Y, Akimoto, S, Noda, M, Nasu, Y, Tsushima, T, Ohmori, H, Sakai, H, Saito, Y, Meguro, N, Usami, M, Kotake, T, Suzuki, Y, Arai, Y & Shimazaki, J 1998, 'Clinical evaluation of serum prostate-specific antigen-apha1-antichymotrypsin complex values in diagnosis of prostate cancer: A cooperative study', International Journal of Urology, vol. 5, no. 1, pp. 48-54.
Kuriyama, Manabu ; Ueno, Kazuya ; Uno, Hiromi ; Kawada, Yukimichi ; Akimoto, Susumu ; Noda, Masatoshi ; Nasu, Yasutomo ; Tsushima, Tomoyasu ; Ohmori, Hiroyuki ; Sakai, Hideki ; Saito, Yasushi ; Meguro, Norio ; Usami, Michiyuki ; Kotake, Toshihiko ; Suzuki, Yuji ; Arai, Yoichi ; Shimazaki, Jun. / Clinical evaluation of serum prostate-specific antigen-apha1-antichymotrypsin complex values in diagnosis of prostate cancer : A cooperative study. In: International Journal of Urology. 1998 ; Vol. 5, No. 1. pp. 48-54.
@article{365d204e600a49fda050e279bdc6f55c,
title = "Clinical evaluation of serum prostate-specific antigen-apha1-antichymotrypsin complex values in diagnosis of prostate cancer: A cooperative study",
abstract = "Background: We studied the clinical significance of serum prostate-specific antigen bound to α1-antichymotrypsin (PSA-ACT) values determined with a newly developed enzyme immunoassay. Methods: Serum PSA-ACT values were determined in a total of 652 sera. Clinical utility for the diagnosis of prostate cancer was compared to that of Tandem-RPSA and γ-seminoprotein (γ-Sm). The new enzyme immunoassay is based on the use of the Stanford reference as an international standard for PSA assays. Results: Serum PSA-ACT values ranged from less than 0.10 to 1.4 ng/mL in healthy males (n = 100) while values in patients with benign prostatic hyperplasia (n = 155) averaged 3.4 ± 3.8 ng/mL (mean ± SD). In patients with prostate cancer, serum PSA-ACT values increased significantly with progression of the clinical stage and there were statistically significant differences between benign prostatic hyperplasia and each stage of prostate cancer except for stage A. Using BPH levels as controls (4.8 ng/mL for PSA-ACT, 7.2 ng/mL for PSA, 3.8 ng/mL for γ-Sm, and 2.4 ng/mL for the complexed/free PSA ratio of PSA-ACT/γ-Sm), specificity was 80{\%}. The sensitivity of prostate cancer detection was 79{\%} for PSA-ACT, 77{\%} for PSA, 57{\%} for γ-Sm, and 46{\%} for the ratio between PSA-ACT/γ-Sm. Conclusion: Although the determination of serum PSA-ACT showed essentially the same utility as that of PSA for the diagnosis of prostate cancer, PSA-ACT may allow prediction of the clinical stage. The PSA-ACT assay may therefore replace PSA in the detection of prostate cancer.",
keywords = "Diagnosis, Prostate cancer, PSA, PSA-ACT, Screening",
author = "Manabu Kuriyama and Kazuya Ueno and Hiromi Uno and Yukimichi Kawada and Susumu Akimoto and Masatoshi Noda and Yasutomo Nasu and Tomoyasu Tsushima and Hiroyuki Ohmori and Hideki Sakai and Yasushi Saito and Norio Meguro and Michiyuki Usami and Toshihiko Kotake and Yuji Suzuki and Yoichi Arai and Jun Shimazaki",
year = "1998",
language = "English",
volume = "5",
pages = "48--54",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Clinical evaluation of serum prostate-specific antigen-apha1-antichymotrypsin complex values in diagnosis of prostate cancer

T2 - A cooperative study

AU - Kuriyama, Manabu

AU - Ueno, Kazuya

AU - Uno, Hiromi

AU - Kawada, Yukimichi

AU - Akimoto, Susumu

AU - Noda, Masatoshi

AU - Nasu, Yasutomo

AU - Tsushima, Tomoyasu

AU - Ohmori, Hiroyuki

AU - Sakai, Hideki

AU - Saito, Yasushi

AU - Meguro, Norio

AU - Usami, Michiyuki

AU - Kotake, Toshihiko

AU - Suzuki, Yuji

AU - Arai, Yoichi

AU - Shimazaki, Jun

PY - 1998

Y1 - 1998

N2 - Background: We studied the clinical significance of serum prostate-specific antigen bound to α1-antichymotrypsin (PSA-ACT) values determined with a newly developed enzyme immunoassay. Methods: Serum PSA-ACT values were determined in a total of 652 sera. Clinical utility for the diagnosis of prostate cancer was compared to that of Tandem-RPSA and γ-seminoprotein (γ-Sm). The new enzyme immunoassay is based on the use of the Stanford reference as an international standard for PSA assays. Results: Serum PSA-ACT values ranged from less than 0.10 to 1.4 ng/mL in healthy males (n = 100) while values in patients with benign prostatic hyperplasia (n = 155) averaged 3.4 ± 3.8 ng/mL (mean ± SD). In patients with prostate cancer, serum PSA-ACT values increased significantly with progression of the clinical stage and there were statistically significant differences between benign prostatic hyperplasia and each stage of prostate cancer except for stage A. Using BPH levels as controls (4.8 ng/mL for PSA-ACT, 7.2 ng/mL for PSA, 3.8 ng/mL for γ-Sm, and 2.4 ng/mL for the complexed/free PSA ratio of PSA-ACT/γ-Sm), specificity was 80%. The sensitivity of prostate cancer detection was 79% for PSA-ACT, 77% for PSA, 57% for γ-Sm, and 46% for the ratio between PSA-ACT/γ-Sm. Conclusion: Although the determination of serum PSA-ACT showed essentially the same utility as that of PSA for the diagnosis of prostate cancer, PSA-ACT may allow prediction of the clinical stage. The PSA-ACT assay may therefore replace PSA in the detection of prostate cancer.

AB - Background: We studied the clinical significance of serum prostate-specific antigen bound to α1-antichymotrypsin (PSA-ACT) values determined with a newly developed enzyme immunoassay. Methods: Serum PSA-ACT values were determined in a total of 652 sera. Clinical utility for the diagnosis of prostate cancer was compared to that of Tandem-RPSA and γ-seminoprotein (γ-Sm). The new enzyme immunoassay is based on the use of the Stanford reference as an international standard for PSA assays. Results: Serum PSA-ACT values ranged from less than 0.10 to 1.4 ng/mL in healthy males (n = 100) while values in patients with benign prostatic hyperplasia (n = 155) averaged 3.4 ± 3.8 ng/mL (mean ± SD). In patients with prostate cancer, serum PSA-ACT values increased significantly with progression of the clinical stage and there were statistically significant differences between benign prostatic hyperplasia and each stage of prostate cancer except for stage A. Using BPH levels as controls (4.8 ng/mL for PSA-ACT, 7.2 ng/mL for PSA, 3.8 ng/mL for γ-Sm, and 2.4 ng/mL for the complexed/free PSA ratio of PSA-ACT/γ-Sm), specificity was 80%. The sensitivity of prostate cancer detection was 79% for PSA-ACT, 77% for PSA, 57% for γ-Sm, and 46% for the ratio between PSA-ACT/γ-Sm. Conclusion: Although the determination of serum PSA-ACT showed essentially the same utility as that of PSA for the diagnosis of prostate cancer, PSA-ACT may allow prediction of the clinical stage. The PSA-ACT assay may therefore replace PSA in the detection of prostate cancer.

KW - Diagnosis

KW - Prostate cancer

KW - PSA

KW - PSA-ACT

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=6844237665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6844237665&partnerID=8YFLogxK

M3 - Article

C2 - 9535601

AN - SCOPUS:6844237665

VL - 5

SP - 48

EP - 54

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 1

ER -